Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PfSPZ-GA1 genetically attenuated malaria parasite safety and efficacy study
NL-OMON46209Active, not recruiting
- Sponsor
- Sanaria Inc.
- Start
- May 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of PfSPZ-GA1 in malaria and Falciparum malaria (PF) (7 arms), sponsored by Sanaria Inc. Primary endpoints: Presence of blood stage parasites after inoculation with PfSPZ-GA1 and Frequency and magnitude of adverse events. Started May 2017; status: active, not recruiting.
02
Drugs
PfSPZ-GA1
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on NL-OMON46209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46209.